SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SANGUINE CORP. (SGNC)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: drdan who wrote (1931)6/27/1998 1:16:00 AM
From: Andrew H  Read Replies (1) of 5402
 
>>Andrew, could you please tell us why it is so important to know the specific timetable for the applications. As long as the drug gets thru Phase One testing without any surprises about toxicity, pharm firms will be falling over themselves to buy into this company<<

I don't remember saying it was so important to know the specific timetable for the applications. I was more concerned about the specific applications begin sought for approval.

However, it is big assumption that"as long as the drug gets through P1 without any surprises about toxicity, pharms will be falling overthemselves to buy this company." That is merely your opinion of the situation. There is no evidence of this whatsoever, is there? If you can provide such evidence, I would love to see it.

Many companies have gotten blood substitute products through P1 without having been bought out by a large pharm. These products later failed in P2 and P3 trials.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News